Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
Jeffrey A. Cohen(Dartmouth Health), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Ellen M. Mowry(Johns Hopkins University), Maria L. Naylor(Vyne Therapeutics (United States)), Jacqueline Nicholas(OhioHealth), Rajani Rajbhandar(Biogen (United States)), James R. Williams(Cornell University), Mar Tintoré(Vall d'Hebron Hospital Universitari), Ana Zabalza(Universitat Autònoma de Barcelona), Robert T. Naismith(Washington University in St. Louis), Carrie M. Hersh(Cleveland Clinic), Carol M. Singh(Biogen (United States)), Megan Hyland(University of Rochester Medical Center), Robert A Bermel(Cleveland Clinic), Tjalf Ziemssen(University Hospital Carl Gustav Carus), Cynthia Grossman
Cited by 21
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k